GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Switch to:

Biohaven (NYSE:BHVN) Total Revenue Growth Rate (Future 3Y To 5Y Est)

: N/A (As of Today)
View and export this data going back to 2022. Start your Free Trial

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Biohaven's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison

For the Biotechnology subindustry, Biohaven's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Biohaven's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls in comparison to its industry or sector. The grey bar indicates the Total Revenue Growth Rate (Future 3Y To 5Y Est)'s extreme value range as defined by GuruFocus.



Biohaven  (NYSE:BHVN) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Biohaven Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Biohaven's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources

Call This an Off-Label Trade

By Yahoo Finance 2022-11-06

Why Biohaven Stock Skyrocketed Again Today

By Yahoo Finance 2022-10-05